|
TCMBANKIN000107 |
nagilactone b |
|
C19H24O7 |
364.4 g/mol |
CC(C)C1=C2C(C3C4C(CC(C(C4(C2=CC(=O)O1)C)O)O)(C(=O)O3)C)O |
|
TCMBANKIN001366 |
sterol |
|
C17H28O |
248.4 g/mol |
C1CC2CCC3C4CCC(CC4CCC3C2C1)O |
|
TCMBANKIN002879 |
arachidonic acid |
(5Z,8Z,11Z,14Z)-5,8,11,14-icosatetraenoic acid; cis-5,8,11,14-Eicosatetraenoic acid; 3435-81-2; 5Z,8Z,11Z,14Z-icosatetraenoic acid; cis,cis,cis,cis-5,8,11,14-Eicosatetraenoic acid; C00219; ACD; Arachidonsaeure; arachidonicacid; DTXSID40473870; (5Z,8Z,11Z,14Z)-Icosatetraenoic acid; ST069383; 93444-49-6; (14C)Arachidonic acid; NCGC00094608-04; 5,8,11,14-Eicosatetraenoic acid, labeled with carbon-14, (all-Z)-; A3555_SIGMA; 5Z,8Z,11Z,14Z-eicosatetraenoic acid; all-cis-5,8,11,14-eicosatetraenoic acid; IDI1_034009; ARACHIDONIC ACID, [1-14C]-; BSPBio_001539; NCGC00094608-02; NCGC00094608-03; AIDS045704; CHEBI:15843; NCGC00094608-01; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid; cis-Delta(5,8,11,14)-eicosatetraenoic acid; A3925_SIGMA; ACM3435812; Spectrum5_001910; Arachidonic acid-carboxy-14C; A9673_SIGMA; LMFA01030001; AIDS-045704; 10931_FLUKA; <i>cis,cis,cis,cis</i>-5,8,11,14-Eicosatetraenoic Acid |
C20H32O2 |
304.5 g/mol |
CCCCCC=CCC=CCC=CCC=CCCCC(=O)O |
|
TCMBANKIN009498 |
dibutyl hydroxytoluene |
|
C15H24O |
220.35 g/mol |
CCCCC1=C(C(=C(C=C1)C)O)CCCC |
|
TCMBANKIN016731 |
arachidonate |
CBiol_001948; KBio2_000511; KBio2_005395; Bio1_000234; SpecPlus_000727; 5,8,11,14-icosatetraenoate; Eicosanetetraenoic acid; (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoic acid; AI3-09613; Spectrum4_000905; KBio2_003079; KBio3_000518; KBioSS_000511; KBio2_002827; CCRIS 6312; KBioSS_000259; (all-Z)-5,8,11,14-Eicosatetraenoic acid; 7771-44-0; Spectrum_000091; KBioGR_001370; Bio2_000739; CHEBI:36306; LMFA01030393; Bio1_001212; KBio2_000259; KBio1_001767; KBioGR_000259; Bio2_000259; 5,8,11,14-Eicosatetraenoic acid / 5,8,11,14-icosatetraenoic acid; KBio2_005647; 506-32-1; DivK1c_006823; Bio1_000723; KBio3_000517; arachidonic acid; EINECS 208-033-4; (5Z,8Z,11Z,14Z)-5,8,11,14-Eikosatetraensaeure; 5,8,11,14-Eicosatetraenoic acid, (all-Z)-; ARACHIDONIC_ACID; Icosa-5,8,11,14-tetraenoic acid |
C20H32O2 |
304.47 |
CCCCCC=CCC=CCC=CCC=CCCCC(=O)[O-] |
|
TCMBANKIN017939 |
α-lindane |
|
C6H6Cl6 or ClCH(CHCl)4CHCl |
|
C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl |
|
TCMBANKIN030237 |
androgen |
|
C22H32O3 |
344.5 g/mol |
CCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C |
|
TCMBANKIN036825 |
Honokiol |
VZ32385; 354H746; NCGC00163567-01; HMS2051C12; 11513CCO0N; {1,1'-Biphenyl]-2,4'-diol, 3,5-di-2-propenyl-; 2-(4-hydroxy-3-prop-2-enyl-phenyl)-4-prop-2-enyl-phenol; ZINC00001536; STK801954; AIDS002243; FVYXIJYOAGAUQK-UHFFFAOYSA-N; AC-486; SMP2_000040; 5,3′ C10630; AX8008971; NSC-293100; AS-15333; W-2613; 3',5-diallyl-2,4'-biphenyldiol; AC1Q7A9U; MLS000759481; TR-014635; 564-73-8; SR-01000758208-5; 3',5-Dipropenyl-(1,1'-biphenyl)-2,4'-diol; J10347; NC00114; SAM001246690; Bio-0326; MLS001423980; CHEBI:5759; 3'',5-diallylbiphenyl-2,4''-diol; REGID_for_CID_72303; O900; MolPort-002-507-432; SCHEMBL133034; InChI=1/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H; BC205226; AN-15767; ANW-56605; MCULE-5001549020; ACN-035410; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; Honokiol, >=98% (HPLC), powder; D04DQJ; CTK5J3931; BG01559998; SR-01000758208; BRD-K98493452-001-01-6; AC1L2HTG; AB0016711; AKOS005622639; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; AT-5464; 5,3''''-Diallyl-biphenyl-2,4''''-diol; RTR-014635; cid_72303; 2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; CHEMBL16901; 3',5-Diallyl-2,4'-dihydroxybiphenyl; 35354-74-6; 5,3′-Diallyl-2,4′-dihydroxybiphenyl; houpa; UNII-11513CCO0N; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; CPD000387107; HY-N0003; HMS3393C12; Honokiol; Q-100425; FT-0601638; 5,3''-Diallyl-biphenyl-2,4''-diol; 3'',5-di-2-propenyl-1,1''-biphenyl-2,4''-diol; BBL027819; MFCD00016674; CCG-100864; ST24044036; AK-25837; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propen-1-yl-; Honokiol, analytical standard; AJ-08043; BDBM50157304; 3',1'-biphenyl)-2,4'-diol; 5,3'-Diallyl-biphenyl-2,4'-diol; NSC293100; NCGC00163567-03; BG00615873; 4CN-0876; NSC 293100; H4914_SIGMA; KS-00000NQF; 3',5'-Diallyl-2,4'-biphenyldiol; SC-17371; BN0719; NCGC00163567-02; LS-174528; BB_NC-1461; s2310; 5,3'-Diallyl-2,4'-dihydroxybiphenyl; API0002927; CS-1696; I06-0428; N1672; HMS2271J07; DTXSID30188845; SMR000387107; MLS001048916; AIDS-002243; HMS3656G03; Honokiol, HO; Honokiol, European Pharmacopoeia (EP) Reference Standard; ZINC1536; Honokiol,(S); MLS006011755; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; 5,3′-Diallyl-2,4′-dihydroxydiphenyl; 4-allyl-2-(3-allyl-4-hydroxyphenyl)phenol; 3',5-Diallylbiphenyl-2,4'-diol |
|
266.334 |
|
|
TCMBANKIN036832 |
daidzein |
486-66-8; AIDS-059333; ST057515; KBio2_005871; CCRIS 7600; 7-Hydroxy-3-(4-hydroxy- phenyl)- chromone; SPBio_000205; AIDS059333; 4′,7-Dihydroxy- iso- flavone; nchembio.2007.28-comp31; KBio2_003303; Spectrum3_000191; Isoflavone, 4',7-dihydroxy- (8CI); Oprea1_182317; 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one; Spectrum5_000857; NCGC00025156-01; BiomolKI_000060; S00273; NCGC00015365-01; KBio1_001023; BiomolKI2_000066; KBioSS_000735; Daidzeol; SMP1_000089; 7,4'-Dihydroxyisoflavone; 7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; C10208; SPECTRUM200789; nchembio.76-comp16; BSPBio_001741; NCGC00025156-09; Daidzein (6CI); 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-; BRN 0231523; 5-18-04-00089 (Beilstein Handbook Reference); Daidzein; Daidzein (4',7-Dihydroxyisoflavone); KBioGR_002432; NINDS_001023; KBio2_000735; ACon1_000543; NCGC00025156-07; ZINC00047551; daidzein ; NCGC00025156-02; Lopac-D-7802; Tocris-1417; 7-hydroxy-3-(4-hydroxyphenyl)chromone; ACon0_001477; 7-Hydroxy-3-(4-hydroxy-phenyl)-chromone; KBio3_001241; DivK1c_001023; Spectrum4_001964; K 251b; UPCMLD-DP052:001; IDI1_001023; MEGxm0_000123; Lopac0_000412; D7802_SIGMA; Spectrum2_000053; EINECS 207-635-4; Spectrum_000255; 4′,7-Dihydroxyisoflavone; NCGC00025156-05; 4',7-Dihydroxy-iso-flavone; NCGC00025156-04; 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-hydroxy-3-(4-hydroxyphenyl)-4-chromenone; 7-Hydroxy-3-(4-hydroxy- phenyl)-4H-1-benzo- pyran-4-one; EU-0100412; CHEBI:28197; SDCCGMLS-0066422.P001; 4',7-Dihydroxyisoflavone; Oprea1_305345 |
C15H10O4 |
254.238 |
c1([H])c(C(=O)C(c2c([H])c([H])c(O[H])c([H])c2[H])=C([H])O3)c3c([H])c(O[H])c1[H] |
|
TCMBANKIN036841 |
prostaglandin a1 |
(13E,15S)-15-hydroxy-9-oxoprosta-10,13-dien-1-oate; CHEBI:57398; prostaglandin A1(1-); prostaglandin A1 anion |
C20H31O4- |
335.5 g/mol |
CCCCCC(C=CC1C=CC(=O)C1CCCCCCC(=O)[O-])O |
|
TCMBANKIN058205 |
trans-resveratrol |
(E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene |
C14H12O3 |
228.24 g/mol |
C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O |
|
TCMBANKIN058229 |
daidzein |
Daidzei; 486-66-8; AIDS-059333; ST057515; KBio2_005871; CCRIS 7600; 7-Hydroxy-3-(4-hydroxy- phenyl)- chromone; SPBio_000205; AIDS059333; 4′,7-Dihydroxy- iso- flavone; nchembio.2007.28-comp31; KBio2_003303; Spectrum3_000191; Isoflavone, 4',7-dihydroxy- (8CI); Oprea1_182317; 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one; Spectrum5_000857; NCGC00025156-01; BiomolKI_000060; S00273; NCGC00015365-01; KBio1_001023; BiomolKI2_000066; KBioSS_000735; Daidzeol; SMP1_000089; 7,4'-Dihydroxyisoflavone; 7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; C10208; SPECTRUM200789; nchembio.76-comp16; BSPBio_001741; NCGC00025156-09; Daidzein (6CI); 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-; BRN 0231523; 5-18-04-00089 (Beilstein Handbook Reference); Daidzein; Daidzein (4',7-Dihydroxyisoflavone); KBioGR_002432; NINDS_001023; KBio2_000735; ACon1_000543; NCGC00025156-07; ZINC00047551; daidzein ; NCGC00025156-02; Lopac-D-7802; Tocris-1417; 7-hydroxy-3-(4-hydroxyphenyl)chromone; ACon0_001477; 7-Hydroxy-3-(4-hydroxy-phenyl)-chromone; KBio3_001241; DivK1c_001023; Spectrum4_001964; K 251b; UPCMLD-DP052:001; IDI1_001023; MEGxm0_000123; Lopac0_000412; D7802_SIGMA; Spectrum2_000053; EINECS 207-635-4; Spectrum_000255; 4′,7-Dihydroxyisoflavone; NCGC00025156-05; 4',7-Dihydroxy-iso-flavone; NCGC00025156-04; 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-hydroxy-3-(4-hydroxyphenyl)-4-chromenone; 7-Hydroxy-3-(4-hydroxy- phenyl)-4H-1-benzo- pyran-4-one; EU-0100412; CHEBI:28197; SDCCGMLS-0066422.P001; 4',7-Dihydroxyisoflavone; Oprea1_305345 |
C15H10O4 |
254.24 |
C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O |
|
TCMBANKIN058519 |
(-)-epigallocatechin-3-gallate; (-)-epigallocatechin 3-o-gallate;epigallocatechin gallate; galloyl-l-epigallocatechol; epigallocatechin 3-gallate; (-)-epigallocatechin gallate; |
KBio2_000796; SpecPlus_000277; 50299_FLUKA; Spectrum3_000244; KBioGR_002002; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] ester; MLS000758300; DivK1c_006373; (−)-Epigallocatechin gallate; EGCG; SPBio_000035; (−)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; KBioSS_000796; Epigallocatechin gallate; Spectrum4_001541; (-)-epigallocatechin 3-gallate; Tea catechin; AIDS000674; KBio2_005932; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromanyl] ester; KBio1_001317; 989-51-5; AIDS-000674; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); KBio2_003364; Galloyl-L-epigallocatechol; SDCCGMLS-0066550.P001; (-)-Epigallocatechol gallate; ACon1_001054; Spectrum5_000102; Green tea extract; MEGxp0_001166; C09731; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; (-)-Epigallocatechin gallate; CCRIS 3729; Teavigo; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Spectrum2_000168; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; (−)-cis-3,3′,4′,5,5′,7-Hexahydroxy-flavane-3-gallate; CHEBI:4806; (-)-epigallocatechin-3-gallate ; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; SPECTRUM210239; E4143_SIAL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; Spectrum_000316; (-)-EGCG; KBio3_001128; BSPBio_001628; Epigallocatechol, 3-gallate, (-)-; Epigallocatechin-3-gallate; E4268_SIAL; epigallocatechin gallate ; epigallocatechin-3-gallate; (-)epigallocatechin-3-gallate ; EGCG; 989E515; [5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 2,3,4-trihydroxybenzoate; HMS2051K21; CS-1258; AC1L22IG; AK165605; Green tea polyphenols, Anagen; (-)-Epigallocatechin-3-O-gallate, United States Pharmacopeia (USP) Reference Standard; AKOS015918182; CAS-989-51-5; Epigallocatechin gallate, primary pharmaceutical reference standard; W-5069; (-)-cis-3,3',4',5,5',7-Hexahydroxy-flavane-3-gallate; (-)-Epigallocatechin gallate, analytical standard; Q-100914; DSSTox_RID_78830; AN-15867; DSSTox_GSID_29889; (-)-Epigallocatechol gallate; FT-0604392; NCGC00164319-04; Green tea extract; MEGxp0_001166; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; N1874; CHEBI:4806; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; BG00814299; HMS3649E08; D0E9DB; Epigallocatechol, 3-gallate, (-)-; (-)-EpigallocatechinGallateHydrate; Epigallocatechin-3-gallate; AB0014381; BQM438CTEL; NC00078; ST51055716; Epigallocatechin gallate, Pharmaceutical Secondary Standard; Certified Reference Material; SpecPlus_000277; Spectrum3_000244; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl-3,4,5-trihydroxybenzoate; MLS000758300; (-)-Epigallocatechin gallate (EGCG); CCG-38378; Gallic acid, 3-ester with epigallocatechol, (-)-; SR-01000946601-1; NCGC00164319-01; (-)-cis-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1(2H)-benzopyran-3-yl Gallate; NCGC00164319-06; DSSTox_CID_567; MCULE-3341525983; Epigallocatechin monogallate, B; Tox21_303457; SAM001247031; 4awm; K791; 989-51-5; SR-01000946601; MFCD00075940; EGCG analogs; Galloyl-L-epigallocatechol; NCGC00164319-03; (-)-Epigallocatechin gallate, >=80% (HPLC), from green tea; Spectrum5_000102; CPD000449288; (-)-Epigallocatechin gallate; LMPK12030005; E0694; Teavigo; Epigallocatechin gallate analogs, Anagen; Epigallocatechin-3-monogallate; ACN-035233; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; Sunphenon; Epigallocatechin gallate(EGCG); s2250; PF-EGCg 90; 3,4-Dihydro-5,7-dihydroxy-2R-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3R-yl-3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxybenzoic acid (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; MLS001424000; (-)-EGCG; ZINC3870412; KBio2_000796; EGCG cpd; KBioGR_002002; Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-; EGCG, Anagen; NCGC00257243-01; Tox21_201468; L-Epigallocatechin gallate; cid_65064; SPBio_000035; BG01747388; Epigallocatechin gallate; KBioSS_000796; Spectrum4_001541; (-)-epigallocatechin 3-gallate; DB12116; EPIGALOCATECHIN GALLATE; ANTIOXIDANT MODEL (TRAMP) -EPIGALLOCATECHIN GALLATE; KBio2_005932; I14-7747; D0U2BH; MCULE-7760530136; 2kdh; Epigallocatechin gallate, Anagen; AOB2839; SDCCGMLS-0066550.P001; 863-65-0; FR-109; ST097428; ACon1_001054; LS-2197; CCRIS 3729; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Epigallocate; GTPL7002; BDBM50070942; C22H18O11; GTPs,Anagen; SCHEMBL35258; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; MolPort-001-741-358; DivK1c_006373; KB-206444; SR-01000759328; Teavigo;; EGCG; (-)-EPIGALLOCATECHIN GALLATE (GREEN TEA EXTRACT); HY-13653; (-)-Epigallocatechin gallate, >=95%; NCGC00259019-01; Tea catechin; DS-9030; SR-01000759328-6; SR-01000759328-5; KDH; AC1Q5X0Z; KBio1_001317; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxyb enzoate; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); NVP-XAA 723; KBio2_003364; EBD2138593; FT-0082796; NCGC00164319-02; C09731; (-)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; UNII-BQM438CTEL; DTXSID1029889; WMBWREPUVVBILR-WIYYLYMNSA-N; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; (-)-Epigallocatehin gallate; Spectrum2_000168; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; (-)-Epigallocatechin gallat; SPECTRUM210239; Epigallocic acid; Epigallocatcchin Gallate; KS-0000132O; BP-30205; CHEMBL297453; SC-47284; Spectrum_000316; 3oob; (-)-Epigallocatechin gallate, >=97.0% (HPLC); KBio3_001128; BSPBio_001628; epigallo-catechin gallate |
C22H18O11 |
458.4g/mol |
C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O |
|
TCMBANKIN059710 |
cryptoxanthin |
|
C40H56O |
552.87 |
CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CC(CC2(C)C)O)C)C)C |
|
TCMBANKIN059827 |
phenol,2,6-bis(1,1-dimethylethyl)-4-methyl |
|
C15H24O |
220.35 g/mol |
CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C |
|
TCMBANKIN060645 |
lovastatin |
|
C24H36O5 |
404.5 g/mol |
CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C |
|
TCMBANKIN060702 |
EPA |
|
C20H30O2 |
302.45 |
CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O |
|
TCMBANKIN060704 |
(z,z,z)-9,12,15-octadecatrienoic acid |
|
C18H30O2 |
278.4 g/mol |
CCC=CCC=CCC=CCCCCCCCC(=O)O |
|
TCMBANKIN060873 |
arachidonic acid |
|
C20H32O2 |
304.5 g/mol |
CCCCCC=CCC=CCC=CCC=CCCCC(=O)O |
|
TCMBANKIN060879 |
Linolic acid |
|
C18H32O2 |
280.4 g/mol |
CCCCCC=CCC=CCCCCCCCC(=O)O |
滇IICP备16009434号-1 |
Dai SX Lab